Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Leases (2019 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Current Leases for 7 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 3.58% to $14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Dec 2025, down 3.58% year-over-year, with the annual reading at $14.0 million for FY2025, 3.58% down from the prior year.
  • Current Leases hit $14.0 million in Q4 2025 for Integra Lifesciences Holdings, up from $13.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $16.3 million in Q1 2024 to a low of $12.7 million in Q2 2022.
  • Historically, Current Leases has averaged $14.4 million across 5 years, with a median of $14.4 million in 2022.
  • Biggest five-year swings in Current Leases: increased 15.27% in 2021 and later dropped 13.08% in 2025.
  • Year by year, Current Leases stood at $14.8 million in 2021, then decreased by 1.02% to $14.6 million in 2022, then rose by 4.51% to $15.3 million in 2023, then decreased by 4.87% to $14.5 million in 2024, then fell by 3.58% to $14.0 million in 2025.
  • Business Quant data shows Current Leases for IART at $14.0 million in Q4 2025, $13.8 million in Q3 2025, and $14.2 million in Q2 2025.